Online citations, reference lists, and bibliographies.
← Back to Search

Safety, Tolerability And Pharmacokinetics Of The Fibroblast Growth Factor Receptor Inhibitor AZD4547 In Japanese Patients With Advanced Solid Tumours: A Phase I Study

H. Saka, C. Kitagawa, Y. Kogure, Y. Takahashi, K. Fujikawa, T. Sagawa, S. Iwasa, N. Takahashi, Taro Fukao, C. Tchinou, D. Landers, Y. Yamada
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
SummaryBackground AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor (FGFR) inhibitor in clinical development for treating tumours with a range of FGFR aberrations, including FGFR mutations, amplifications and fusions. Methods This open-label, Phase I, multicentre study (NCT01213160) evaluated the safety, pharmacokinetics, and preliminary antitumour efficacy (RECIST v1.1) of AZD4547 monotherapy in Japanese patients with advanced solid tumours. Part A was a dose-escalation part; Part B was a dose-expansion part in patients with FGFR-amplified tumours, confirmed by fluorescence in situ hybridization. Results Thirty patients enrolled in Part A (dose range: 40 mg twice daily [bid] to 120 mg bid; 160 mg once daily [qd]), four in Part B (80 mg bid). No dose-limiting toxicities were observed and maximum tolerated dose was not determined. Most common adverse events (AEs; any grade) were: dysgeusia (50% of patients); stomatitis (41%); diarrhoea (38%); hyperphosphataemia (38%); dry mouth (35%). Common grade ≥3 AEs were nausea (12% of patients) and neutropenia (9%). No complete or partial responses were observed: 21/30 patients had stable disease ≥4 weeks in Part A, and 1/4 patients had stable disease ≥10 weeks in Part B. Following single and multiple dosing, absorption rate appeared moderate; peak plasma concentrations generally occurred 3–4 h post-dose, then declined biphasically with terminal half-life ~30 h. Steady state was reached by day 8. Compared with single dosing, plasma concentrations were, on average, 2.4- and 3.3- to 5.4-fold higher after qd and bid dosing, respectively. Conclusions AZD4547 was well tolerated in Japanese patients, with best response of stable disease ≥4 weeks.
This paper references
10.1200/JCO.2016.34.15_SUPPL.4521
FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.
R. Jones (2016)
10.1200/JCO.2014.32.15_SUPPL.2620
A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.
H. Arkenau (2014)
10.1038/nrc2780
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
: current progress , unresolved questions and future directions
O Casanovas (2005)
2016) BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer
T Powles (2016)
A phase 2 trial of ponatinib in Philadelphia chromosomepositive leukemias
JE Cortes (2013)
10.1056/NEJMOA065044
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
10.1200/JCO.2016.34.15_SUPPL.TPS4577
BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.
T. Powles (2016)
Genomic characterization and targeted therapeutics in squamous cell lung cancer
P Hammerman (2011)
10.1172/JCI39703
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Taylor (2009)
10.1038/ncponc0558
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
I. Weinstein (2006)
10.1080/01926230590961845
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Alan P. Brown (2005)
A phase 2 study of BGJ 398 in patients ( pts ) with advanced or metastatic FGFR - altered cholangiocarcinoma ( CCA ) who failed or are intolerant to platinum - based chemotherapy
MM Javle (2016)
10.1200/JCO.2014.60.7341
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
J. Tabernero (2015)
10.1200/JCO.2014.32.15_SUPPL.8034
Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.
L. Nogova (2014)
Phase I dose-escalation study of JNJ42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero (2015)
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer 8:59–60
JD Robertson (2009)
10.1200/JCO.2015.33.15_SUPPL.2508
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
E. Smyth (2015)
10.1016/S1470-2045(13)70586-2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
10.1200/JCO.2015.33.15_SUPPL.4014
A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.
Y. Bang (2015)
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
L V Sequist (2014)
A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
TT Batchelor (2008)
Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebocontrolled phase 3 trial
WT van Der Graaf (2012)
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
F. Courjal (1997)
10.1016/S1470-2045(15)00366-6
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
A. Du Bois (2016)
AZD4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
TJ Yao (2015)
10.1016/S0140-6736(12)60651-5
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
W. Graaf (2012)
10.1007/s13277-015-3237-1
AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
Ting-jing Yao (2015)
10.1016/j.ejca.2012.12.010
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
C. Sternberg (2013)
10.1200/JCO.2005.23.16_SUPPL.LBA4510
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
B. Escudier (2005)
10.1200/JCO.2008.19.5511
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
B. Escudier (2009)
10.1155/2012/950508
Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer
K. Holzmann (2012)
10.1056/NEJMoa1406470
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
M. Schlumberger (2015)
10.1158/1078-0432.CCR-12-2694
Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Jingchuan Zhang (2012)
BekaiiSaab TS (2016) A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy
MM Javle (2016)
10.1038/12615
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
D. Cappellen (1999)
10.18632/ONCOTARGET.2987
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
J. Chang (2015)
10.1158/1538-7445.AM2013-LB-145
Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .
F. André (2013)
10.1056/NEJMc081780
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
10.1007/s10456-014-9420-y
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
N. Vasudev (2014)
10.1158/0008-5472.CAN-11-3034
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
P. Gavine (2012)
10.1200/JCO.2016.34.15_SUPPL.2500
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
D. Hyman (2016)
10.3816/CCC.2009.n.010
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
J. Robertson (2009)
10.1007/s10555-015-9579-8
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
T. Helsten (2015)
10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A. Grothey (2013)
Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind
W T Van Der Graaf (2012)
10.1200/JCO.2007.12.7712
Shortening the timeline of pediatric phase I trials: the rolling six design.
J. Skolnik (2008)
10.1200/JCO.2008.20.1293
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
R. Motzer (2009)
10.1073/pnas.0803379105
Drug-sensitive FGFR2 mutations in endometrial carcinoma
A. Dutt (2008)
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
J. Ledermann (2013)
10.1158/1078-0432.CCR-12-3898
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
L. Xie (2013)
10.1200/JCO.2008.21.3223
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
S. Sleijfer (2009)
10.1158/2159-8290.CD-15-1246
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
A. Pearson (2016)
10.1200/JCO.2015.62.7380
Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?
J. Lewin (2015)
10.1016/J.CYTOGFR.2005.01.001
Cellular signaling by fibroblast growth factor receptors.
V. P. Eswarakumar (2005)
10.1200/JCO.2016.34.15_SUPPL.TPS4575
A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations.
A. Siefker-Radtke (2016)
10.1200/JCO.2009.24.8252
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
S. Kopetz (2010)
10.1158/2159-8290.CD-18-0229
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
S. Pal (2018)
10.1158/1078-0432.CCR-13-3006
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
B. Escudier (2014)
10.1016/S1470-2045(08)70285-7
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng (2009)
10.1016/J.YDBIO.2005.09.011
Functions and regulations of fibroblast growth factor signaling during embryonic development.
B. Thisse (2005)
A Phase III randomized study comparing the efficacy of cediranib asmonotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients
T Batchelor (2010)
Anti - angiogenic therapy for
NS Vasudev (2014)
Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically Invest New Drugs
LV Sequist (2014)
Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors
F. André (2013)
10.1200/JCO.2009.23.9764
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
C. Sternberg (2010)
10.1016/J.CCR.2005.09.005
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
O. Casanovas (2005)
Genomic characterization and targeted therapeutics in squamous cell lung cancer. 14th World Conference on Lung Cancer
P Hammerman
10.1056/NEJMoa1306494
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
J. E. Cortes (2013)
2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
A du Bois (2016)
10.1200/JCO.2016.34.4_SUPPL.335
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
M. Javle (2016)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled
A Grothey (2013)
10.1158/1538-7445.AM2014-CT326
Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
L. Sequist (2014)
10.1200/JCO.2016.34.15_SUPPL.4517
Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.
S. Pal (2016)
10.1158/1538-7445.AM2008-LB-247
Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
T. Batchelor (2008)



This paper is referenced by
10.1007/s10637-020-00933-2
Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
Nikki Phanhthilath (2020)
10.3390/molecules23030698
Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors
Alan Jiang (2018)
10.1111/cas.14265
First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
Takafumi Koyama (2019)
10.1177/1933719118802053
Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis
Nao Kato (2019)
10.1097/IGC.0000000000001129
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
S. Taurin (2018)
10.18632/aging.102286
Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
Li-ping Shan (2019)
10.1200/JCO.19.02630
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Y. Chae (2020)
10.1245/s10434-018-07145-2
Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14
Tomohisa Okuno (2018)
10.1038/bjc.2017.330
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. Papadopoulos (2017)
10.3390/cells8060536
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
A. Raja (2019)
10.3390/molecules22040583
Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors
Y. Zhang (2017)
10.1007/978-981-13-1486-5_1
HGFR and FGR2: Their Roles in Progression and Metastasis of Esophageal Cancer
R. Kumar (2018)
10.1186/s40164-019-0149-6
Targeted and novel therapy in advanced gastric cancer
Julie H. Selim (2019)
10.1002/mc.23012
Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma
Alok R. Khandelwal (2019)
10.1186/s40164-019-0130-4
Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
Jeffrey Ahn (2019)
10.1158/1078-0432.CCR-19-2035
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
F. Facchinetti (2019)
10.4155/fmc-2018-0103
Recent developments and advances of FGFR as a potential target in cancer.
Wen-jun Xue (2018)
10.1016/j.lungcan.2019.12.018
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
10.1016/j.ijrobp.2020.03.040
Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
M. Fisher (2020)
10.1080/13543784.2017.1316714
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
E. Rijavec (2017)
10.3390/cancers12082010
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
T. Yamamoto (2020)
10.1016/j.ctrv.2019.06.003
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
A. Mahipal (2019)
Semantic Scholar Logo Some data provided by SemanticScholar